Literature DB >> 31600767

Prophylactic efficacy of 5-HT4R agonists against stress.

Briana K Chen1, Indira Mendez-David2, Victor M Luna3, Charlène Faye2, Alain M Gardier2, Denis J David2, Christine A Denny4,5.   

Abstract

Enhancing stress resilience could protect against stress-induced psychiatric disorders in at-risk populations. We and others have previously reported that (R,S)-ketamine acts as a prophylactic against stress when administered 1 week before stress. While we have shown that the selective 5-hydroxytryptamine (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is ineffective as a prophylactic, we hypothesized that other serotonergic compounds such as serotonin 4 receptor (5-HT4R) agonists could act as prophylactics. We tested if three 5-HT4R agonists with varying affinity could protect against stress in two mouse strains by utilizing chronic corticosterone (CORT) administration or contextual fear conditioning (CFC). Mice were administered saline, (R,S)-ketamine, Flx, RS-67,333, prucalopride, or PF-04995274 at varying doses, and then 1 week later were subjected to chronic CORT or CFC. In C57BL/6N mice, chronic Flx administration attenuated CORT-induced weight changes and increased open-arm entries in the elevated plus maze (EPM). Chronic RS-67,333 administration attenuated CORT-mediated weight changes and protected against depressive- and anxiety-like behavior. In 129S6/SvEv mice, RS-67,333 attenuated learned fear in male, but not female mice. RS-67,333 was ineffective against stress-induced depressive-like behavior in the forced swim test (FST), but prevented anxiety-like behavior in both sexes. Prucalopride and PF-04995274 attenuated learned fear and decreased stress-induced depressive-like behavior. Electrophysiological recordings following (R,S)-ketamine or prucalopride administration revealed that both drugs alter AMPA receptor-mediated synaptic transmission in CA3. These data show that in addition to (R,S)-ketamine, 5-HT4R agonists are also effective prophylactics against stress, suggesting that the 5-HT4R may be a novel target for prophylactic drug development.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31600767      PMCID: PMC6969048          DOI: 10.1038/s41386-019-0540-3

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  57 in total

1.  Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.

Authors:  Rebecca A Brachman; Josephine C McGowan; Jennifer N Perusini; Sean C Lim; Thu Ha Pham; Charlene Faye; Alain M Gardier; Indira Mendez-David; Denis J David; René Hen; Christine A Denny
Journal:  Biol Psychiatry       Date:  2015-05-04       Impact factor: 13.382

2.  Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress.

Authors:  Josephine C McGowan; Collin Hill; Alessia Mastrodonato; Christina T LaGamma; Alexander Kitayev; Rebecca A Brachman; Niven R Narain; Michael A Kiebish; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2018-03-29       Impact factor: 7.853

3.  Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section.

Authors:  Jia-Hui Ma; Sai-Ying Wang; He-Ya Yu; Dan-Yang Li; Shi-Chao Luo; Shan-Shan Zheng; Li-Fei Wan; Kai-Ming Duan
Journal:  Psychiatry Res       Date:  2019-03-16       Impact factor: 3.222

4.  Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial.

Authors:  Yang Xu; Yuantao Li; Xiaolei Huang; Daili Chen; Baozuan She; Daqing Ma
Journal:  Arch Gynecol Obstet       Date:  2017-03-29       Impact factor: 2.344

5.  Prophylactic Ketamine Attenuates Learned Fear.

Authors:  Josephine C McGowan; Christina T LaGamma; Sean C Lim; Melina Tsitsiklis; Yuval Neria; Rebecca A Brachman; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2017-01-27       Impact factor: 7.853

6.  The intraoperative administration of ketamine to burned U.S. service members does not increase the incidence of post-traumatic stress disorder.

Authors:  Laura L McGhee; Christopher V Maani; Thomas H Garza; Terry M Slater; Lawrence N Petz; Marcie Fowler
Journal:  Mil Med       Date:  2014-08       Impact factor: 1.437

7.  Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy Against Stress-Induced Depressive-like Behavior.

Authors:  Alessia Mastrodonato; Randy Martinez; Ina P Pavlova; Christina T LaGamma; Rebecca A Brachman; Alfred J Robison; Christine A Denny
Journal:  Biol Psychiatry       Date:  2018-02-23       Impact factor: 13.382

8.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12

9.  Group II metabotropic glutamate receptor blockade promotes stress resilience in mice.

Authors:  Jaclyn N Highland; Panos Zanos; Polymnia Georgiou; Todd D Gould
Journal:  Neuropsychopharmacology       Date:  2019-04-02       Impact factor: 8.294

10.  Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress.

Authors:  Jose Amat; Samuel D Dolzani; Scott Tilden; John P Christianson; Kenneth H Kubala; Kristi Bartholomay; Katherine Sperr; Nicholas Ciancio; Linda R Watkins; Steven F Maier
Journal:  J Neurosci       Date:  2016-01-06       Impact factor: 6.167

View more
  8 in total

Review 1.  Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.

Authors:  Millie Rincón-Cortés; Anthony A Grace
Journal:  Behav Brain Res       Date:  2019-11-15       Impact factor: 3.332

Review 2.  Harnessing the Neurobiology of Resilience to Protect the Mental Well-Being of Healthcare Workers During the COVID-19 Pandemic.

Authors:  Ravi Philip Rajkumar
Journal:  Front Psychol       Date:  2021-03-18

3.  The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study.

Authors:  Søren Vinther Larsen; Brice Ozenne; Kristin Köhler-Forsberg; Asbjørn Seenithamby Poulsen; Vibeke Høyrup Dam; Claus Svarer; Gitte Moos Knudsen; Martin Balslev Jørgensen; Vibe Gedso Frokjaer
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-11       Impact factor: 5.555

4.  The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain.

Authors:  Angharad N de Cates; Marieke A G Martens; Lucy C Wright; Cassandra D Gould van Praag; Liliana P Capitão; Daisy Gibson; Philip J Cowen; Catherine J Harmer; Susannah E Murphy
Journal:  Front Psychiatry       Date:  2022-04-12       Impact factor: 5.435

5.  Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study.

Authors:  Kristin Köhler-Forsberg; Brice Ozenne; Søren V Larsen; Asbjørn S Poulsen; Elizabeth B Landman; Vibeke H Dam; Cheng-Teng Ip; Anders Jørgensen; Claus Svarer; Gitte M Knudsen; Vibe G Frokjaer; Martin B Jørgensen
Journal:  Transl Psychiatry       Date:  2022-07-11       Impact factor: 7.989

Review 6.  Novel drug developmental strategies for treatment-resistant depression.

Authors:  Éva Borbély; Mária Simon; Eberhard Fuchs; Ove Wiborg; Boldizsár Czéh; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2022-01-26       Impact factor: 9.473

7.  Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning Without Sensorimotor Deficits.

Authors:  Briana K Chen; Gwenaëlle Le Pen; Adam Eckmier; Gilles Rubinstenn; Therese M Jay; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

8.  Déjà-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task.

Authors:  Angharad N de Cates; Lucy C Wright; Marieke A G Martens; Daisy Gibson; Cagdas Türkmen; Nicola Filippini; Philip J Cowen; Catherine J Harmer; Susannah E Murphy
Journal:  Transl Psychiatry       Date:  2021-10-04       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.